-
Mashup Score: 0Showcase Overview - American Urological Association - 7 month(s) ago
During the annual AUA Innovation Nexus Conference, a select group of the most innovative investigators, startups, and mid-size companies are selected to become part of the Showcase session. Showcase candidates pitch their innovations to a panel of seasoned investors and successful innovators during the world’s premier urology innovation and research incubator conference. The Showcase is an ideal platform for individuals and companies to present new concepts to those looking to invest in urology innovatio
Source: auanexus.orgCategories: Latest Headlines, UrologyTweet
-
Mashup Score: 0AHA Advisory Focuses on Cardiovascular-Kidney-Metabolic Syndrome - Renal and Urology News - 7 month(s) ago
A major goal of the initiative is to reduce fragmentation of medical care for the growing numbers of patients who have diabetes, obesity, chronic kidney disease, or cardiovascular risk for cardiovascular-kidney-metabolic syndrome.
Source: www.renalandurologynews.comCategories: Latest Headlines, UrologyTweet-
The American Heart Association has shined a spotlight on Cardiovascular-#Kidney-Metabolic (CKM) syndrome, including staging, prediction, and approaches to holistic care. CKM syndrome replaces cardiorenal syndrome and cardiometabolic disease. https://t.co/rnEHGn7XTT
-
-
Mashup Score: 0A Primer on Peer Review - American Urological Association - 7 month(s) ago
Whether you are a resident who wants to get started as a peer reviewer, a current reviewer interested in honing your approach, or even a seasoned reviewer interested in mentoring new reviewers, we invite you to join us for this free webinar series featuring leaders from around the urological world. Sponsored by The Journal of Urology ® and hosted by Dr George Koch, there is something for everyone in this fun and informative webinar
Source: www.auanews.netCategories: Latest Headlines, UrologyTweet-
🚨 Check out the latest FREE tutorials: A Primer on Peer Review with Drs. Joyner, Seideman, Ghani, and Talwar. Click here ➡️ https://t.co/md1mabJeI4 @CaseySeidemanMD @RuchikaTalwarMD https://t.co/YLVPzVyO3A
-
-
Mashup Score: 0NICE has recently moved the IRE guidelines from ‘Research Only’ to ‘Special Arrangements’ - 7 month(s) ago
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Read our Cookies
Source: www.urologynews.uk.comCategories: Latest Headlines, UrologyTweet-
📢NICE has upgraded the IRE guidelines, opening doors for better access to the AngioDynamics NanoKnife IRE ablation system in the UK. Patients undergoing focal therapy for prostate cancer can now experience an improved quality of life. https://t.co/0IiOl2oc6Z @Aquilant_Endo
-
-
Mashup Score: 0Pelvic Floor Muscle Training No Better Than Bladder Training for Overactive Bladder - Renal and Urology News - 7 month(s) ago
Twelve weeks of supervised pelvic floor muscle training does not provide further improvements in terms of urinary symptoms
Source: www.renalandurologynews.comCategories: Latest Headlines, UrologyTweet-
For women with overactive bladder symptoms, supervised pelvic floor muscle training (PFMT) does not provide additional improvement over bladder training. https://t.co/RyhNEeTQge
-
-
Mashup Score: 0Active surveillance should be considered for select men with Grade Group 2 prostate cancer - BMC Urology - 7 month(s) ago
Background Treatment decisions for localized prostate cancer must balance patient preferences, oncologic risk, and preservation of sexual, urinary and bowel function. While Active Surveillance (AS) is the recommended option for men with Grade Group 1 (Gleason Score 3 + 3 = 6) prostate cancer without other intermediate-risk features, men with Grade Group 2 (Gleason Score 3 + 4 = 7) are typically recommended active treatment. For select patients, AS can be a possible initial management strategy for men with Grade Group 2. Herein, we review current urology guidelines and the urologic literature regarding recommendations and evidence for AS for this patient group. Main body AS benefits men with prostate cancer by maintaining their current quality of life and avoiding treatment side effects. AS protocols with close follow up always allow for an option to change course and pursue curative treatment. All the major guideline organizations now include Grade Group 2 disease with slightly differi
Source: bmcurol.biomedcentral.comCategories: Latest Headlines, UrologyTweet-
Two Comments published in BMC urology discuss AS in patients with intermediate-risk, grade group 2 prostate cancer, highlighting how AS should not be routinely used in this population, but might be offered to selected patients https://t.co/C9l16SZNhC https://t.co/Fe6YuBm9WR
-
-
Mashup Score: 0NCCN: Cancer Centers Still Experiencing Shortages of Chemo Drugs - Renal and Urology News - 7 month(s) ago
Overall, 72% and 59% of 26 cancer centers reported shortages in carboplatin and cisplatin
Source: www.renalandurologynews.comCategories: Latest Headlines, UrologyTweet-
Many cancer centers are still experiencing a shortage of carboplatin, cisplatin, and other chemotherapy drugs, according to the results of a follow-up survey conducted by the National Comprehensive Cancer Network (NCCN). https://t.co/gLEMzUMdPG
-
-
Mashup Score: 0
“Our results provide molecular insights for potential therapeutic strategies to treat prostate cancer and other AR-involved diseases by targeting AR multivalent interactions,” said Zhijie “Jason” Liu, PhD.
Source: www.urologytimes.comCategories: Latest Headlines, UrologyTweet-
Alterations of certain molecular interactions could generate new strategies for the treatment of prostate cancer and related diseases, according to findings from a recent study. #urology #urologist #pcsm #prostatecancer Read more here: https://t.co/tVNYg2qN3y
-
-
Mashup Score: 0
Efforts to improve recovery after radical cystectomy (RC) are needed.To investigate wrist-worn wearable activity trackers in RC participants.An observ…
Source: www.sciencedirect.comCategories: Latest Headlines, UrologyTweet-
Digital Tracking of Patients Undergoing Radical Cystectomy for Bladder... https://t.co/ahith3ygcg
-
-
Mashup Score: 6
On October 16, 2023, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) with platinum-containing chemotherapy as neoadjuvant treatment, and with continuation of single-agent pembrolizumab as post-surgical adjuvant treatment for resectable (tumors ≥4 cm or node positive) non-sm
Source: www.fda.govCategories: Latest Headlines, UrologyTweet-
RT @DipeshUpretyMD: FDA approves perioperative Pembrolizumab for resectable NSCLC #LCSM @OncoAlert @BTFCancerNews https://t.co/3rIvj61VMk
-
🚨🚨DEADLINE APPROACHING!🚨🚨 Are you interested in presenting at the 2024 Innovation Nexus Showcase? Submit your application to pitch by October 19, 2023. Learn more ➡️ https://t.co/TmwdINdysq https://t.co/2Ef3olICNS